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Purpose: Harms of prostate cancer treatment on urinary health related quality
of life have been thoroughly studied. In this study we evaluated not only the
harms but also the potential benefits of prostate cancer treatment in relieving
the pretreatment urinary symptom burden.
Materials and Methods: In American (1,021) and Spanish (539) multicenter
prospective cohorts of men with localized prostate cancer we evaluated the
effects of radical prostatectomy, external radiotherapy or brachytherapy in
relieving pretreatment urinary symptoms and in inducing urinary symptoms de
novo, measured by changes in urinary medication use and patient reported
urinary bother.
Results: Urinary symptom burden improved in 23% and worsened in 28% of
subjects after prostate cancer treatment in the American cohort. Urinary
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Abbreviations
and Acronyms
AUA-SI ¼ American Urological
Association Symptom Index
BMI ¼ body mass index
BT ¼ brachytherapy
EPIC-26 ¼ Expanded Prostate
Cancer Index Composite short
form
HRQOL ¼ health related quality of
life
LUTS ¼ lower urinary tract
symptoms
PROST-QA ¼ Prostate Cancer
Outcomes and Satisfaction with
Treatment Quality Assessment
RP ¼ radical prostatectomy
XRT ¼ external radiotherapy
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medication use rates before treatment and 2 years after treatment were 15% and 6% with radical prosta-
tectomy, 22% and 26% with external radiotherapy, and 19% and 46% with brachytherapy, respectively.
Pretreatment urinary medication use (OR 1.4, 95% CI 1.0e2.0, p ¼ 0.04) and pretreatment moderate lower
urinary tract symptoms (OR 2.8, 95% CI 2.2e3.6) predicted prostate cancer treatment associated relief of
baseline urinary symptom burden. Subjects with pretreatment lower urinary tract symptoms who underwent
radical prostatectomy experienced the greatest relief of pretreatment symptoms (OR 4.3, 95% CI 3.0e6.1),
despite the development of deleterious de novo urinary incontinence in some men. The magnitude of pre-
treatment urinary symptom burden and beneficial effect of cancer treatment on those symptoms were verified
in the Spanish cohort.
Conclusions:Men with pretreatment lower urinary tract symptoms may experience benefit rather than harm
in overall urinary outcome from primary prostate cancer treatment. Practitioners should consider the full
spectrum of urinary symptom burden evident before prostate cancer treatment in treatment decisions.
Key Words: prostatic neoplasms, quality of life, outcome assessment (health care), surveys and
questionnaires, patient-centered care
DEFINITIVE treatment of localized prostate cancer
often occurs in an age distribution of men in whom
preexisting LUTS from benign prostatic hyperplasia
or the local effects of prostate cancer are already a
significant health problem.1e3 However, most anal-
yses do not account for baseline urinary health
related quality of life, and focus purely on the
negative effects of treatment, failing to consider the
full spectrum of potential posttreatment changes in
urinary symptom burden, including the possibility
of symptom relief.
While several prospective multicenter studies
have investigated the effects of prostate cancer
treatment on urinary HRQOL,4e10 few have exam-
ined urinary medication use and/or operative in-
terventions, and most have focused on urinary
incontinence as the primary outcome. The relative
degree to which patients are bothered by urinary
incontinence and LUTS is unclear. Outcomes are
often reported as changes in mean HRQOL scores
across treatment groups, which favors a one size fits
all approach that obscures the diversity of individ-
ual changes within treatment groups, ie who is
getting worse, staying the same or getting better.
Achievement of patient centered care and individ-
ualized adjustment of urinary outcome expectations
requires an understanding of how patient pre-
treatment HRQOL and other factors may influence
the potential for symptom worsening or symptom
relief after treatment.11
We previously described a multicenter, prospec-
tive study evaluating HRQOL outcomes after RP,
XRT and BT.12 To better understand which patients
experience a worsened, unchanged or improved
urinary symptom burden after prostate cancer
treatment, as well as the relative impact of urinary
incontinence and LUTS, we reevaluated this cohort
after all participants had completed at least 2 years
of followup, and described urinary medication use,
operative interventions and changes in overall uri-
nary symptom burden. We used ordinal logistic
regression to identify significant predictors of
urinary outcome changes after prostate cancer
treatment.
METHODS
Study Subjects
The PROST-QA cohort consists of 1,201 men with previ-
ously untreated stage T1 to T2 prostate cancer. They were
enrolled from 2003 to 2006 at 9 university affiliated hos-
pitals into an institutional review board approved protocol
after providing written informed consent. We analyzed
the 1,021 cohort participants who had complete 2-year
urinary HRQOL followup, including 522 treated with
RP, 239 who received XRT and 260 treated with BT.
Treatment
RP was performed with open retropubic (335) or laparo-
scopic/robotic (187) techniques.13e15 Overall 92% of pa-
tients underwent unilateral or bilateral nerve sparing
surgery. Of the men who underwent XRT 84% had in-
tensity modulated radiation therapy (the remainder had
conformal beam) and 31% received neoadjuvant hormonal
therapy. BT was performed transperineally with perma-
nent low dose rate isotopes (typically I-125).12 Adjuvant/
salvage hormonal therapy rates within 2 years were low
(less than 5%).
Outcome Measures
Patient reported outcomes were collected prospectively by
a third party telephone survey facility before treatment
through 2 years after treatment. We measured urinary
incontinence using the EPIC-26,16 and we measured
LUTS using the EPIC-26 and the AUA-SI.1 We measured
subject global urinary symptom burden with the EPIC-26
overall urinary bother question, “Overall, how much of a
problem has your urinary function been for you?”
measured on a 5-point Likert scale (no problem to big
problem).
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Case report forms collected data on urinary medication
use before and after treatment as well as the incidence of
operative interventions. Operative interventions were
categorized as 1) urinary reconstruction, eg artificial uri-
nary sphincter, male urinary sling, urethroplasty; 2) hos-
pitalization for urinary complication; 3) endoscopic/
minimally invasive intervention with intent to repair/di-
agnose a urinary complication; 4) any urinary catheteri-
zation and 5) diagnostic cystoscopy. An adjudication panel
comprised of a nontreating urologist and radiation oncol-
ogist blinded to treatment type determined operative
category. The principal investigator resolved lack of
consensus. Subjects with multiple interventions in the
same category were counted once and those with in-
terventions in different categories were counted once per
category. We classified urinary medications as alpha
blockers, 5-alpha reductase inhibitors and anticholiner-
gics. Pretreatment medications excluded the prophylactic
initiation of alpha blockers immediately before BT.
Statistical Considerations
We used longitudinal logistic regression with generalized
estimating equations to compare the use of urinary med-
ications among groups over time, and logistic regression
to compare the incidence of urinary interventions among
groups.
In each treatment group we examined how each indi-
vidual subject’s overall symptom burden changed from
before treatment to 2 years after treatment. To capture
the magnitude and direction of change we categorized this
bother change into a 5-item ordinal scale of 2dmajor
worsening, 1dminor worsening, 0dno change, 1d
minor improvement and 2dmajor improvement, where
minor indicates a 1-point change and major refers to a 2-
point or greater change. We used ordinal logistic regres-
sion to identify factors that predicted a higher ordinal
score across all levels of urinary bother change (ie a more
favorable or less unfavorable change in urinary symptom
burden). Several covariates were considered, including
age, race, cohabitation, education level, comorbidities,
BMI, D’Amico risk group,17 prostate size, pretreatment
use of urinary medications, pretreatment LUTS and pre-
treatment incontinence. We used backward elimination to
identify the variables retained in the multivariable model
with an inclusion threshold of p <0.10. We tested for
interaction between treatment group and the strongest
outcome predictor.
External Validation
The Multicentric Spanish Group of Clinically Localized
Prostate Cancer,10 known as the Spanish cohort, served
as an external validation cohort. Of the 614 subjects who
completed the 2-year followup and met the Spanish cohort
original inclusion and exclusion criteria, 539 had the
equivalent demographic and HRQOL information from
before treatment to 2 years after treatment that was
examined in the PROST-QA analysis. Several covariates
including medication use were not available for compari-
son. To determine whether the factors predictive of uri-
nary outcome change would replicate in an independent
cohort, we performed ordinal logistic regression as previ-
ously described.
RESULTS
We describe treatment group characteristics in
table 1 ½T1as well as previously described detailed
trends in urinary HRQOL from before treatment to
2 years after treatment.12 Pretreatment inconti-
nence was rare (table 2) ½T2. Pretreatment moderate to
severe LUTS were common throughout the cohort
Table 1. Pretreatment patient and disease characteristics in the PROST-QA cohort
RP XRT BT Overall
Median age at enrollment (IQR)* 60 (56e65) 69 (63e74) 66 (61e71) 63 (58e69)
No. race (%):*
African-American 25 (5) 34 (14) 28 (11) 87 (9)
Other 497 (95) 205 (86) 232 (89) 934 (91)
Median kg/m2 BMI (IQR) 27 (25e30) 28 (25e31) 28 (25e31) 28 (25e31)
No. cohabitation (%)* 456 (87) 187 (78) 207 (80) 850 (83)
No. comorbidities (%):*
0e1 402 (77) 144 (60) 172 (66) 718 (70)
2 82 (16) 58 (24) 59 (23) 199 (19)
3þ 38 (7) 37 (15) 29 (11) 104 (10)
Median ml prostate vol (IQR)* 40 (30e52) 42 (30e59) 36 (28e47) 39 (30e53)
Median ng/ml PSA (IQR)* 5.5 (4.2e7.5) 6.3 (4.3e9.7) 5.2 (4.2e6.8) 5.5 (4.2e7.8)
No. clinical T stage (%):*
cT1 374 (72) 164 (69) 214 (82) 752 (74)
cT2 148 (28) 75 (31) 46 (18) 269 (26)
No. Gleason score on initial biopsy (%):*
6 or Less 316 (61) 105 (44) 199 (77) 620 (61)
7 181 (35) 100 (42) 60 (23) 341 (33)
8e10 25 (5) 34 (14) 1 (0) 60 (6)
No. D’Amico risk group (%):17,*
Low 275 (53) 84 (35) 184 (71) 543 (53)
Intermediate 205 (39) 106 (44) 72 (28) 383 (38)
High 42 (8) 49 (21) 4 (2) 95 (9)
*Treatment groups differed in distributions of age, race, marital/living status, number of comorbidities, prostate volume, PSA, clinical stage, Gleason score and D’Amico risk
group (each p <0.01).12
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(37%) and least common in those who received
BT (29%).
Subjects treated with RP had a clinically signifi-
cant decrease (worsening) in mean EPIC-26 incon-
tinence score (14  24 points, p <0.001)18 and a
clinically significant increase in mean EPIC-26
irritation/obstruction score (improved LUTS) 2
years after treatment (5  15, p <0.001). Subjects
who received BT had clinically significant wors-
ening of mean incontinence (6  19 points,
p <0.001) and irritation/obstruction (6  18,
p <0.001) scores from before to 2 years after
treatment.
Urinary Medication Use and Operative
Intervention
The pretreatment rate of urinary medication use
differed among the groups (p ¼ 0.03) and was lowest
in those treated with RP. The proportion of subjects
treated with RP requiring urinary medications
decreased significantly from before (15%) to after
treatment (6%). Of the 76 men in the RP group
taking a pretreatment urinary medication 84% were
able to discontinue the medication and 28% started
a new medication, most commonly an anticholin-
ergic (supplementary table 1, http://jurology.com/).
Urinary medication use was unchanged after XRT
(26% vs 22% before treatment). After brachytherapy
urinary medication use increased significantly (46%
vs 19% before treatment, p <0.001), with 43% of
patients taking alpha blockers at 2 years compared
to 14% before treatment. Overall 75 (36%) subjects
in the BT group who were not taking urinary med-
ications before BT started and remained on a
new urinary medication at 2 years after BT
(supplementary table 1, http://jurology.com/).
The rate of operative interventions for post-
treatment urinary complications was not statisti-
cally significantly different among the treatment
groups (p ¼ 0.20, table 2). Most urinary recon-
structive procedures were performed in the RP
group. The BT group had the highest proportion of
men undergoing unplanned urethral catheteriza-
tion and diagnostic cystoscopy.
Changes in Overall Urinary Symptom Burden
We examined how subjects’ global perception of
urinary symptom burden (overall urinary bother)
Table 2. Urinary HRQOL, urinary medication use and posttreatment operative intervention
RP XRT BT
Before
Treatment
2 Yrs after
Treatment
Before
Treatment
2 Yrs after
Treatment
Before
Treatment
2 Yrs after
Treatment
Mean  SD EPIC-26 urinary incontinence score16 94  13 80  23 93  13 89  16 94  11 88  19
No. EPIC-26 urinary incontinence score (%):
No/very small problem with leakage of urine 490 (94) 384 (73) 222 (93) 198 (83) 248 (95) 214 (82)
Small problem with leakage of urine 23 (4) 98 (19) 13 (5) 32 (13) 10 (4) 29 (11)
Moderate-big problem with leakage of urine 9 (2) 40 (8) 4 (2) 9 (4) 2 (1) 17 (7)
Mean  SD EPIC-26 urinary irritation/obstruction score 87  15 92  11 87  13 89  14 90  12 84  17
No. AUA-SI score (%):*,1
Mild (0e7) 314 (60) 145 (61) 186 (72)
Moderate (8e19) 173 (33) 87 (36) 70 (27)
Severe (20e35) 35 (7) 7 (3) 4 (1)
No. requiring urinary medications (%):
Any urinary medication† 76 (15) 32 (6) 52 (22) 55 (26) 50 (19) 109 (46)
Alpha blocker 66 (13) 9 (2) 38 (16) 50 (23) 38 (15) 103 (43)
5-Alpha reductase inhibitor 1 (0) 1 (0) 3 (1) 4 (2) 2 (1) 2 (1)
Anticholinergic 4 (1) 23 (5) 3 (1) 10 (5) 1 (0) 22 (9)
No. need for operative intervention (%):‡
All operative interventions§ – 36 (7) – 13 (5) – 25 (10)
Urinary reconstructive procedures 8 (2) 2 (1) 1 (0)
Hospitalization for urinary complication 1 (0) 1 (0) 1 (0)
Endoscopic/percutaneous intervention/stricture diagnosis 18 (3) 3 (1) 6 (2)
Unplanned urinary catheterization 11 (2) 2 (1) 15 (6)
Diagnostic cystoscopy without stricture 11 (2) 7 (3) 12 (5)
No. overall urinary bother (%):
No problem 296 (56) 290 (55) 120 (50) 128 (53) 158 (60) 117 (45)
Very small problem 95 (18) 121 (23) 62 (26) 51 (21) 58 (22) 54 (21)
Small problem 74 (14) 75 (14) 33 (14) 37 (15) 24 (9) 52 (20)
Moderate problem 49 (9) 27 (5) 24 (10) 20 (8) 16 (6) 28 (11)
Big problem 8 (2) 9 (2) 0 (0) 3 (1) 4 (2) 9 (3)
* Pretreatment LUTS as measured by AUA-SI were significantly different among treatment groups (p <0.01).
† Changes between pretreatment and 2 years were significant for RP and BT (each p <0.001). Differences in 2-year medication use at 2 years were significant among groups
(p <0.001).
‡ Between 6 months and 2 years after treatment, except for urinary reconstructive procedure, which was assessed between treatment start and 2 years. Patients listed only
once in each category.
§No statistically significant differences in operative intervention among treatment groups (p ¼ 0.20).
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changed from before treatment to 2 years after
treatment (supplementary tables 2e5, http://
jurology.com/). Of the entire cohort 23% reported
improvement and 28% reported worsening of uri-
nary problems. The RP and XRT treatment groups
each had approximately equal proportions of sub-
jects perceiving urinary improvement and wors-
ening (28% and 27% for RP; 25% and 24% for XRT,
respectively). The proportion of the RP group with
moderate to severe urinary bother decreased from
11% to 7% after treatment (p ¼ 0.01), despite worse
overall incontinence. This proportion was un-
changed in the XRT group and significantly
increased in the BT group (8% before BT vs 14%
after BT, p ¼ 0.005), with subjects who were more
likely to have worsened urinary problems 2 years
after treatment (37% worsened, 12% improved).
We then performed multivariable ordinal logistic
regression to identify pretreatment factors predic-
tive of favorable pretreatment to posttreatment
change in overall urinary symptom burden over a
5-point ordinal scale from major worsening to major
improvement (table 3)½T3 . For all treatment groups the
most powerful positive predictor of favorable (or less
unfavorable) change in urinary bother was the
presence of moderate to severe (AUA-SI 8 or
greater) pretreatment LUTS (OR 2.8, 95% CI
2.2e3.6, p <0.001). Pretreatment urinary medica-
tion use was also a significant positive predictor (OR
1.4, 95% CI 1.0e2.0, p ¼ 0.04). Baseline inconti-
nence was not significant (p ¼ 0.4).
There was significant effect modification between
the most powerful outcome predictor (baseline
LUTS) and treatment group (p ¼ 0.003, table 3).
This was especially pronounced in subjects treated
with RP, for whom having pretreatment LUTS
conferred a greater than 4 times higher odds of
urinary symptom relief from before to after
treatment (OR 4.3, 95% CI 3.0e6.1, p <0.001). This
interaction between treatment group and pretreat-
ment LUTS is illustrated in the figure ½F1. Of the sub-
jects in the RP group with pretreatment LUTS 52%
reported improvement in urinary bother after
treatment and 21% reported worsening. Of the 52
(10%) subjects treated with RP with pretreatment
LUTS and urinary medication use 76% reported
improvement (48% major, 28% minor) after RP
(supplementary table 6, http://jurology.com/). More
patients in the BT group with preexisting LUTS had
symptom worsening vs improvement after treat-
ment (31% and 26%, respectively).
We found similar results on analysis of a sepa-
rate, previously described Spanish cohort
(supplementary table 7, http://jurology.com/). On
ordinal logistic regression pretreatment LUTS was
the most significant predictor of favorable change in
overall urinary bother (OR 1.7, p ¼ 0.01), and there
was significant interaction between this effect and
treatment group (p ¼ 0.01). The effect of pretreat-
ment LUTS on favorable urinary bother change was
again most prominent with RP (OR 4.15, p <0.001),
but nonsignificant for XRT and BT (OR 0.85 and
1.66, respectively, p >0.05).
Relative Impact of Urinary Incontinence and
Irritation/Obstruction
We then investigated the relative effects of incon-
tinence and irritation/obstruction on overall urinary
bother by further evaluating those in the RP group
who reported pretreatment moderate to severe
LUTS (table 4) ½T4. Most subjects whose urinary in-
continence after RP was mild (0 to 1 pads per day)
preferred their posttreatment urinary state to their
pretreatment state (63% of patients reported
improvement, 10% reported symptom worsening),
while severe incontinence (3þ pads per day)
negated any relief gained from improvement in
LUTS. Overall urinary bother for all subjects was
more closely correlated with urinary irritation/
obstruction score (Spearman correlation 0.70) than
urinary incontinence score (Spearman correla-
tion 0.55).
DISCUSSION
The deleterious effects of prostate cancer treatment
on urinary function have been studied exten-
sively.5,19e22 Our study highlights the prevalence
and importance of burdensome pretreatment uri-
nary problems in men with prostate cancer, and
further examines how treatment induced changes
affect patients’ urinary quality of life, an inherently
subjective concept that incorporates patients’ indi-
vidual perceptions of problems and the efforts
required to mitigate them.
Table 3. Association of individual patient factors with odds of
favorable change in overall urinary bother from before to 2
years after treatment
OR 95% CI p Value
Pretreatment urinary medication use 1.4 1.0e2.0 0.04
Moderate-severe pretreatment LUTS:* 2.8 2.2e3.6 <0.001
RP 4.3 3.0e6.1 <0.001
XRT 1.9 1.1e3.0 0.01
BT 1.9 1.1e3.1 0.01
Pretreatment urinary incontinence† 1.2 0.8e1.7 0.39
Cohabitation 0.8 0.6e1.0 0.07
2 or More comorbidities 0.8 0.6e1.1 0.13
BMI greater than 35 kg/m2 0.7 0.5e1.0 0.08
Odds ratios were computed based on the multivariable ordinal logistic regression
model. Several covariates were also assessed, but were not statistically signifi-
cant nor suspected to be confounders, including age, cohabitation, race, educa-
tion, D’Amico risk group, prostate size and use of hormonal therapy. Potential
confounders were retained in the model even if not statistically significant.
* The reported odds ratio of 2.8 is without an interaction term present.
†Defined as EPIC-26 urinary incontinence score 70 or less.
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LUTS were a substantial pretreatment problem
in this cohort. Overall 37% of the men had AUA-SI
scores that indicated moderate to severe symptoms
and 17% were on pretreatment urinary medications.
These rates are comparable to those in men of a
similar age without prostate cancer in population
based cohorts,2,3 and are less than those of men on
observation for early stage prostate cancer, of whom
49% reported moderate to severe symptoms.23
To our knowledge, this is the first multicenter
prospective study to report the pretreatment and
posttreatment rate of urinary medication use. Uri-
nary medications may not only influence urinary
HRQOL domain scores, but themselves constitute
an often unmeasured quality of life and cost burden,
as medications being taken 2 years after treatment
are likely needed on a lifelong basis. Our findings
suggest that those studies that report urinary
problems after BT occurring primarily in the acute
setting may fail to account for the increase in alpha
blocker use from before treatment (14%) to after
treatment (43%),7,24,25 and likely underestimate the
long-term effects of treatment.
A Swedish randomized trial comparing RP to
watchful waiting in a cross-sectional analysis found
that a smaller proportion of men experienced post-
treatment obstructive LUTS after RP than watchful
waiting, but was limited by the lack of pretreatment
urinary HRQOL assessment.23 Several other
studies have suggested urinary obstruction relief
after RP,26e28 but neither identified individual
characteristics predisposing to favorable outcome
nor assessed urinary medication use. Most studies
report outcomes as changes in mean function scores,
which can mask changes for individual subjects in
treatment groups. Stratification by pretreatment
function can help elucidate individual changes as
suggested in a single center study.11
We chose to further investigate changes in
subjects’ global perceptions of urinary symptom
burden by examining overall urinary bother,
which encompasses urinary incontinence and
Ordinal change in overall urinary bother from before treatment to 2 years after treatment in PROST-QA cohort, measured as change in
subject response to overall urinary bother item (originally from UCLA-PCI and conserved in EPIC-26 HRQOL instrument16) from before
treatment to 2 years after treatment because item reflects burden of obstructive urinary symptoms as well as urinary incontinence.
Pretreatment obstructive urinary symptoms were measured using AUA-SI (0 to 7dmild symptoms, 8 to 14dmoderate symptoms
and 15 to 35dsevere symptoms).1 Minor refers to 1-point change on UCLA-PCI overall urinary bother item Likert response scale
(eg patient response as having small problem changed to moderate problem or moderate problem to big problem, or vice versa).
Major refers to 2-point or greater change in overall urinary bother. Percentages in each bar do not add up to 100% because
remaining subjects in each category had no change in urinary symptom burden from before treatment to 2 years after treatment.
Table 4. Effect of posttreatment urinary incontinence severity
on ordinal change in overall urinary bother in patients treated
with RP with moderate to severe pretreatment LUTS
%
No. (% of total)2 1 0 1 2
No. incontinence pads/day:
0 2 1 27 26 44 82 (40)
1 8 11 28 25 28 53 (26)
2 6 32 25 25 13 53 (26)
3þ 32 26 21 16 5 19 (10)
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irritation/obstruction. By analyzing this outcome in
a novel, ordinal fashion, we captured the full spec-
trum of potential changes in urinary quality of life,
including the direction (worsening vs improved) and
degree (major vs minor) of HRQOL change. Our use
of ordinal logistic regression allowed us to identify
pretreatment LUTS as a factor that should not be
ignored when counseling patients on what to expect
in terms of urination after treatment.
Urinary incontinence was a sufficiently substan-
tial problem after RP that more than 20% of subjects
with pretreatment LUTS reported worse overall
urinary problems after surgery despite the potential
for LUTS relief. Previous urinary HRQOL studies
examining urinary function and bother have sug-
gested that subjects may find LUTS more bother-
some than incontinence.20,29 Our data are
consistent with this finding. Subjects treated with
RP reported the lowest rate of posttreatment mod-
erate to severe urinary problems, and those with
pretreatment LUTS mostly found posttreatment
incontinence less bothersome than pretreatment
symptoms as long as the incontinence was mild.
This study has several limitations. As a non-
randomized study, selection bias makes compari-
sons among treatment groups challenging.
However, such comparisons were not a goal of this
analysis as we focused on outcome changes from
before to after treatment in each group and aimed to
identify subject characteristics that may predict a
more favorable posttreatment outcome. While our
results may be affected by floor/ceiling effects, we do
not believe they explain the magnitude of interac-
tion between pretreatment LUTS and treatment
group, especially for RP. Overall urinary bother is a
complex entity that may not only represent a global
assessment of urinary status and function, but may
also encompass more abstract notions such as
perceived cancer cure, coping mechanisms and pa-
tient expectations. However, a patient’s experience
and perception of urinary status may be the ulti-
mate measure of urinary quality of life, an inher-
ently subjective concept.
CONCLUSIONS
The preexisting urinary problems of patients
heavily influence the wide spectrum of changes in
urinary symptom burden seen after prostate cancer
treatment. In a setting where adverse urinary con-
sequences are common, the possibility of identifying
those who may experience urinary symptom
improvement should not be ignored. The impact of
individualized assessment of pretreatment urinary
symptoms and its potential effect on prostate cancer
treatment decision making warrant further study.
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EDITORIAL COMMENT
The findings of the PROST-QA Consortium are a
welcome validation for those who continue to be
enthusiastic regarding prostatectomy. As suggested
by previous reports and long-standing urological
dogma, men with significant pretreatment
LUTS have improved voiding symptoms after
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prostatectomy, as long as incontinence is mild.
Meanwhile, men with significant LUTS who receive
radiation (in particular, brachytherapy) fare worse
after treatment.
One might expect androgen ablation to have an
impact on LUTS. Nevertheless, in a multivariable
model androgen ablation was not a significant factor
for urinary bother. This may be due to a lack of
granular data relating to the relative timing of the
questionnaire and androgen ablation administration.
This study gives us a uniquely nuanced un-
derstanding of urinary symptomatology after
primary treatment.1,2 Importantly these findings
equip providers with guidance for patient selec-
tion. These data will need to be integrated into
future quality adjusted life expectancy decision
analyses to help objectify clinical decision
making.3
Shreyas Joshi and Alexander Kutikov
Department of Surgical Oncology, Division of Urologic Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania
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